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CEvidence-based health-care decision making requires comparisons of all
relevant competing interventions. In the absence of randomized, con-
trolled trials involving a direct comparison of all treatments of interest,
indirect treatment comparisons and networkmeta-analysis provide use-
ful evidence for judiciously selecting the best choice(s) of treatment.
Mixed treatment comparisons, a special case of network meta-analysis,
combinedirect and indirect evidence forparticularpairwise comparisons,
thereby synthesizing a greater share of the available evidence than a tra-
ditional meta-analysis. This report from the ISPOR Indirect Treatment
Comparisons Good Research Practices Task Force provides guidance on
the interpretation of indirect treatment comparisons and network meta-
analysis to assist policymakers and health-care professionals in using its
findings for decisionmaking.We start with an overview of hownetworks O
ortlan
al So
oi:10.1016/j.jval.2011.04.002f randomized, controlled trials allowmultiple treatment comparisons of
ompeting interventions.Next,an introductiontothesynthesisof theavail-
ble evidencewitha focuson terminology, assumptions, validity, and statis-
ical methods is provided, followed by advice on critically reviewing and in-
erpreting an indirect treatment comparison or network meta-analysis to
nformdecisionmaking.Wefinishwithadiscussionofwhattodoif thereare
o direct or indirect treatment comparisons of randomized, controlled trials
ossible and a health-care decision still needs to bemade.
eywords: Bayesian, decision making, comparative effectiveness, indi-
ect treatment comparison, mixed treatment comparison, network
eta-analysis.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Background to the task force
The ISPOR Board of Directors approved the formation of an Indi-
rect Treatment Comparisons Good Research Practices Task Force
to develop good research practices document(s) for indirect treat-
ment comparisons in January 2009. Researchers, experienced in
systematic reviews, network meta-analysis, synthesis of evi-
dence, and related statistical methods working in academia, re-
search organizations, the pharmaceutical industry, or govern-
ment from the United States, Canada, and Europe, were invited to
join the Task Force LeadershipGroup. Several health-care decision
makers who use indirect/mixed treatment comparison evidence
in health-care decisions were also invited. The Task Force met,
primarily by teleconference with an ongoing exchange of email,
and face to face in April 2010 to develop the topics to be addressed,
agree on the outline, and draft the report. The Leadership Group
determined that to adequately address good research practices for
indirect treatment comparisons and the use of these comparisons
in health-care decisions, the Task Force Report would comprise
* Address correspondence to: Jeroen P. Jansen, Mapi Values, 133 P
E-mail: jeroen.jansen@mapivalues.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.two papers: “Interpreting Indirect Treatment Comparisons and
Network Meta-Analysis for Health-Care Decision Making: Report
of the ISPOR Task Force on Indirect Treatment Comparisons Good
Research Practices: Part 1” and “Conducting Indirect Treatment
Comparisons and Network Meta-Analysis Studies: Report of the
ISPOR Task Force on Indirect Treatment Comparisons Good Re-
search Practices: Part 2.” Summaries of the papers were presented
for comment at the 15th Annual International Meeting in Atlanta,
GA, USA, in May 2010. Drafts of the two papers were sent for com-
ment to the Task Force Review Group (103 invited and self-se-
lected individuals interested in this topic) in July 2010. The authors
of the papers considered the comments from the Task Force Re-
view Group, and the revised drafts of the two papers were sent for
comment to the ISPOR membership (5550 members) in September
2010.Altogether, thePart 1paper received23 comments, and thePart
2 paper received 13 comments. All written comments are published
on the ISPOR Web site. The authors of each paper considered all
comments (many of which were substantive and constructive), re-
vised the papers further, and submitted them to Value in Health.
d Street, Boston, MA 02114 USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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The ISPOR Task Force on Indirect Comparisons Good Research
Practices is publishing its report as two papers. This paper relies
on Part 2 of the report [1] for the good research practices for con-
ducting indirect treatments comparisons and networkmeta-anal-
ysis studies.
Systematic reviews of randomized, controlled trials (RCTs) are
considered the standard basis for evidence-based health-care de-
cision making for clinical treatment guidelines and reimburse-
ment policies. Many systematic reviews use meta-analysis to
combine quantitative results of several similar and comparable
studies and summarize the available evidence [2]. Sound decision
making requires comparisons of all relevant competing interven-
tions. Ideally, robustly designed RCTs would simultaneously com-
pare all interventions of interest. Unfortunately, such studies are
almost never available, thereby complicating decision making [3–
6]. New drugs are often compared to placebo or standard care, but
not against each other, in trials aimed to contribute (as expedi-
tiously as possible) to obtaining approval for drug licensing; there
may be no commercial incentive to compare the new treatment to
an active control treatment [5,6]. Even if therewere an incentive to
incorporate competing interventions in an RCT, the interventions
of interest may vary by country or have changed over time due to
new evidence and treatment insights. Therefore, for some indica-
tions, the number of competing interventions makes a trial incor-
porating all of them impractical.
In the absence of trials involving a direct comparison of treat-
ments of interest, an indirect comparison can provide useful evi-
dence of the difference in treatment effects among competing in-
terventions (which otherwisewould be lacking) and for judiciously
selecting the best choice(s) of treatment. For example, if two par-
ticular treatments have never been compared against each other
head to head, but these two treatments have been compared to a
common comparator, then an indirect treatment comparison
(ITC) can use the relative effects of the two treatments versus the
common comparator [7–10].
Although it is often argued that indirect comparisons are
needed when direct comparisons are not available, it is important
to realize that both direct and indirect evidence contributes to the
total body of evidence. The results from indirect evidence com-
bined with the direct evidence may strengthen the assessment
between treatments directly evaluated [3]. Even when the results
of the direct evidence are conclusive, combining them with the
results of indirect estimates in a mixed treatment comparison
(MTC) may yield a more refined and precise estimate of the inter-
ventions directly compared and broaden inference to the popula-
tion sampled because it links andmaximizes existing information
within the network of treatment comparisons [9].
If the available evidence consists of a network ofmultiple RCTs
involving treatments compared directly or indirectly or both, it
can be synthesized by means of so-called network meta-analysis
[11]. In a traditional meta-analysis, all included studies compare
the same intervention with the same comparator. Network meta-
analysis extends this concept by includingmultiple pairwise com-
parisons across a range of interventions and provides estimates of
relative treatment effect on multiple treatment comparisons for
comparative effectiveness purposes. (In this report, the term com-
parative effectiveness is used to refer to any comparison of out-
comes between interventions called relative effectiveness in Eu-
ropean jargon) [12]. We have used comparative effectiveness and
relative treatment effect without making a distinction whether
the evidence base consists of RCTs designed for drug licensing
(efficacy) or real-world pragmatic randomized studies (effective-
ness). Network meta-analysis is about estimating relative treat-
ment effects between competing interventions).Given the great value of ITC and network meta-analysis for ohealth-care decision making and its increasing acceptance (e.g.,
Pharmaceutical Benefits Advisory Committee in Australia, Cana-
dian Agency for Drugs and Technologies in Health, National Insti-
tute for Health and Clinical Excellence [NICE] in the United King-
dom), this report provides practical guidance for policymakers and
other health-care practitioners to enrich their understanding of
these evidence synthesis methods [6,13]. We start with an over-
view of how RCTs of competing interventions form networks of
evidence that allowmultiple treatment comparisons.We thendis-
cuss the synthesis of the available evidence with a focus on termi-
nology, assumptions, validity, and statistical methods, followed
by some advice on critically reviewing and interpreting an ITC or
network meta-analysis. The last section discusses what to do if
there are no direct or indirect treatment comparisons of RCTs pos-
sible and a health-care decision still needs to be made.
Multiple treatment comparisons and evidence
networks
Figure 1 shows networks of increasing complexity in which mul-
tiple treatments have been compared. Each node reflects an inter-
vention, and a line connecting two nodes reflects one or more
RCTs. For every intervention in a connected network, a relative
treatment effect can be estimated versus another intervention.
Suppose that the main comparison of interest is between inter-
vention C and intervention B, but no direct assessment has com-
pared them. In the first network on the left in Figure 1, interven-
tion B has been compared to intervention A in an AB trial, and C
has been compared to A in an AC trial, so an indirect comparison
can estimate the relative treatment effect of C versus B. The ITC of
C versus B is “anchored” on A (we favor this more descriptive term
rather than “adjusted,” which appears in the literature as well). A
could represent an active treatment comparator or placebo. Of key
importance in an ITC is not to “break randomization” [5,10,14]. For
example, if A, B, and C are interventions for rheumatoid arthritis
patients, it is incorrect to simply compare the observed fraction of
responders on drug B in the AB trials to the observed fraction of
responders on drug C in the AC trials. Using the data in this way
fails to separate the efficacy of the drugs from possible placebo
effects (RCTs are designed to separate drug effects from other ef-
fects). Another reason to avoid breaking randomization is that
differences in response may reflect different baseline risks, even
where the relative risk is consistent between trials [5,15]. Using
data only from the treatment arms of interest to draw compari-
sons, omitting the data from the control or placebo arms, is called
a “naïve indirect comparison,” results in bias, and should be
avoided [8]. To preserve the randomization within each trial, one
must compare the relative treatment effects (e.g., compare the
odds ratio for B versus A from the AB trials to the odds ratio for C
versus A from the AC trials).
The second network in Figure 1 would permit an ITC of inter-
entions B, C, D, and E, anchored on the common comparator A.
ecause these interventions are all connected in the network (i.e.,
ach pair has a path from one to the other), indirect comparisons
an be performed for C versus B, D versus B, E versus B, D versus C,
versus C, and E versus. D. An example of such a “star-shaped”
etwork is a recent comparison of bisphosphonate therapies for os-
eoporosis inwhich four competing interventionswere all studied in
lacebo-controlled trials [16]. For someof the interventions,multiple
lacebo-controlled trials were available, and the analysis can be la-
eled a networkmeta-analysis. Another example is the ITC of intra-
oronary drug-eluting stents by Biondi-Zoccai et al. [17].
In the third network, not all trials have a common comparator,
ut all interventions are still connected. Theadditional interventions
andGare connectedwithA, B, C,D, andEby the EF trials and the FG
rials, and an indirect comparison of each intervention with any
ther is possible (although comparisons with longer paths will have
419V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8less precision) [9]. An example is the network meta-analysis of anti-
fungal treatment for confirmed systemic fungal infections [18].
The fourth network structure consists of interventions A, B,
and C (as in the first network), but now head-to-head RCT data are
available for every comparison; the network of evidence consists
of AB trials, AC trials, and BC trials. An important characteristic of
this network is the “closed loop”: each comparison has both direct
and indirect evidence. For example, the BC comparison has direct
evidence from the BC trials and indirect evidence from the AB and
AC trials (and similarly for the AB andAC comparisons). A network
in which some of the pairwise comparisons have both direct and
indirect evidence is called an MTC [3,9]. A recent example of an
MTC comparing three interventions is the study by Stettler et al.
[19] regarding drug-eluting and bare-metal stents.
The fifth network also involves an MTC for interventions A, B,
and C, but interventions A, C, E, and F form another, longer loop.
For networks that contain loops, it is important that the indirect
comparisons be consistent with the direct comparisons, as dis-
cussed in the next section [9,20,21]. Recent examples of network
meta-analysis with loops include the network meta-analysis of
first line antihypertensive therapies by Psaty et al. [22], the study of
stroke prevention among patientswith atrial fibrillation by Cooper
et al. [23], a network meta-analysis of opioids for breakthrough
cancer pain by Vissers et al. [24], and the networkmeta-analysis of
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Fig. 1 – Network meta-analysis of RCTsnew-antidepressants for major depression by Cipriani et al. [25].Salanti et al. [26] provide an overview of different network struc-
tures of some of the recently published studies.
Whatever the structure of the network, pairwise comparisons,
either direct or indirect or both, can be made between interven-
tions that are connected. The terms ITC, MTC, and network meta-
analysis are sometimes used interchangeably. We propose us-
ing network meta-analysis when the evidence base consists of
more than two RCTs connecting more than two interventions. If
the network consists of at least one closed loop, labeling the
analysis an MTC is appropriate. Any analysis of an open-loop
network can be called an ITC. In the remainder of this paper, we
use the term network meta-analysis to refer to synthesis of a
network of trials and only explicitly use ITC or MTC when it
facilitates the explanation and discussion of concepts and as-
sumptions.
Synthesis of the evidence
Assumptions
Given a network of interventions and RCTs comparing them, the
objective of the analysis is to synthesize the results from the indi-
vidual RCTs, thereby obtaining (pooled) estimates of relative treat-
ment effects for pairwise comparisons. Although the comparators
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420 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8is whether the trials in the network are sufficiently similar to yield
meaningful results for the ITC and MTC.
A traditional meta-analysis combines the results of several
RCTs that compared the same interventions, say A and B, to get an
overall estimate of relative effect (e.g., odds ratio, relative risk, or
difference in change from baseline) and a corresponding estimate
of uncertainty. It is important to realize that randomization holds
within each RCT of A and B, but not across the RCTs. Thus, the
trialsmaydiffer on study andpatient characteristics. If these char-
acteristics aremodifiers of the relative treatment effect of B versus
A, then the studies are said to be heterogeneous.
Similarly, in a networkmeta-analysis of RCTs involvingmultiple
treatment comparisons, the randomization holds only within the
individual trials. Relative treatment effects for a particular pairwise
comparison may exhibit heterogeneity. Also, if the trials differ
among the direct comparisons (e.g., AB trials differ from AC trials)
and these differences aremodifiers of the relative treatment effects,
then the estimate of the indirect comparison is biased [8,15,21,27].
Examples of effect modifiers are patient characteristics, the way in
which the outcomes are defined and/or measured, protocol require-
ments such as allowed cotreatment, and the length of follow up. In
otherwords, if thedistributionof interactions between relative treat-
ment effects and covariates is not balanced across trials that are
comparing different sets of interventions, the similarity assumption of
an ITC isviolated,andconfoundingbiases theanalysis [15,21]. Figure 2
depicts the comparisons involved in the similarity assumption of an
ITC. If the AB trials and the AC trials are comparable in effect modi-
fiers, then an indirect estimate for the relative effect of C versus B
(dBC, which can be a difference in normally distributed data, or a log
dds ratio [OR], or log hazards ratio, etc.) can be obtained from the
stimates of the effect of B versus A (dAB) and the effect of C versus A
(dAC): dBC dAC dAB. In essence, this implies that the same true dBC is
btained as would have been estimated in a three-arm ABC trial [9].
When direct evidence and indirect evidence are combined for a
articular pairwise comparison, it is important that the indirect
stimate is not biased and there is no discrepancy between the
irect and indirect comparisons [21,26,28,29]. Therefore, consis-
ency between these direct and indirect comparisons should be
ccounted for. Figure 3 depicts the components involved in the
onsistency assumption. The network has both direct and indirect
vidence of every pairwise comparison of interventions A, B, and
. (For example, dBC can be obtained from the BC trials, but also
ndirectly from theAC trials and theAB trials.) For consistency, the
ollowing equation needs to be satisfied: dBC  dAC  dAB [21,28]. If
there is an imbalance inmodifiers of the relative treatment effects
across studies for one ormore of the comparisons, the consistency
assumptionmay not be justifiable. Consistency only applies to the
loops of evidence. It is notmeaningful to say, for example, that the
AB comparison is consistentwith the AC comparison.We can only
say that the AB, AC, and BC comparisons are consistent. As a
simple example of inconsistency in an ABC network with an AB
trial, an AC trial, and a BC trial, let us assume that the popula-
Indirect comparison
Direct comparison
A        B        C
A
B
C
Fig. 2 – Similarity assumption in an indirect treatment
comparison. AB trials and the AC trials are comparable on
effect modifiers, and an unbiased indirect estimate for the
relative effect of C versus B can be obtained from the
estimates of the effect of B versus A and the effect of Cpversus A.tion OR (ignoring sampling error) of response with treatment B
relative to A is 0.4 (ORAB  0.4) and the OR with C versus A is 0.5
(ORAC  0.5), then we would expect the OR of C versus B to be
ORBCORAC/ORAB 0.5/0.4 1.25. There is inconsistency if the BC
rial shows ORBC 1.25 (of course, in actual MTC analysis, there is
always sampling error, and this kind of strict evaluation of consis-
tency based on the point estimates is not appropriate. Here it aims
to illustrate the inconsistency concept). In summary, heterogene-
ity pertains to variation in the same treatment effect among stud-
ies, whereas evidence inconsistency is the discrepancy between
direct and indirect comparisons.
Analysis
To synthesize the results of the different RCTs in the network and
obtain relative effect estimates for all possible pairwise compari-
sons, an analysismethod needs to be used that preserves random-
ization within trials andminimizes bias due to lack of randomiza-
tion across trials.
In Figure 1, an overview of the analysis methods is presented
and discussed in more detail here below. Whatever the method of
analysis, the pooling of individual study results and indirect com-
parisons should be based on relative effect measures (e.g., OR,
difference in change from baseline, hazards ratio) to preserve ran-
domization. If the network does not consist of loops, the results of
the RCTs available for each of the direct comparisons can be com-
bined by means of multiple traditional meta-analyses (e.g., a
meta-analysis of the AB trials and ameta-analysis of the AC trials)
followed by an indirect comparison of the pooled results of each of
these meta-analyses [7,11].
If the network of interventions consists of a loop, then the
analysis method needs to combine estimates of the direct com-
parisons with estimates of the indirect comparisons. In the ABC
network in which for each of the pairwise comparisons we have
RCTs (network 4 in Fig. 1), the pooled relative treatment effect of
the BC comparison from the BC trials needs to be combined with
the indirect estimate based on the AB trials and the AC trials. The
same applies to the AB and AC comparisons. It is clear that the
more complex the network is, the more burdensome and poten-
tially confusing such a stepwise approach is.
As an alternative to multiple sequential meta-analyses and in-
direct comparisons, a statistical model can be defined that reflects
the mathematical relationships between the relative effect esti-
mates of the direct and indirect comparisons in the complete net-
work [9]. Given a network of A, B, and C comparisons, the relative
effect estimates can be expressed as follows: dBC  dAC  dAB (as-
uming similarity/consistency assumptions hold). When this ex-
Indirect comparison
Direct comparison
A        B        C 
A
B
C
Fig. 3 – Consistency assumption in a mixed treatment
comparison. AB trials, AC trials, and BC trials are
comparable in effect modifiers, and for each pairwise
comparison, the direct and indirect estimates are
consistent.ression is generalized to any network with multiple different in-
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421V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8terventions, the following is obtained: dbk  dAk  dAb, with k the
intervention and b the comparator. Depending on the network, k
can be intervention B, C, D, E, etc. Comparator b can be A, B, C, D,
etc, as long as k is alphabetically after b. This expression implies
that any estimate for a particular pairwise comparison can be ex-
pressed by the relative effect estimates of the intervention and
comparator relative to an overall reference treatment A as long as
all interventions are connected in one network. dAB,dAC, dAD, . . . ,dAk,
are called basic parameters of the model that are estimated based
n the available studies. dBC,dBD,dCD,, and so on are functional param-
eters and can be calculated based on the (pooled) estimates for the
basic parameters [28]. For a network involving K treatments and T
types of comparisons, there are K-1 basic parameters and T K
1 functional parameters. To summarize, a network meta-analysis
model is an extension of a traditional meta-analysis model con-
sisting of not one, but K  1 parameters that need to be estimated
o allow for multiple pairwise comparisons across a range of K
nterventions. Such anetworkmeta-analysismodel applies to net-
orks with and without loops, i.e., both ITCs and MTCs.
Network meta-analysis can be performed with fixed- or ran-
om-effectsmodels.With a fixed-effectsmodel, it is assumed that
here is no variation in relative treatment effects across studies for
particular pairwise comparison [15,30]. Observed differences for
particular comparison among study results are solely due to
hance. For any given treatment comparison in a fixed-effects
odel, the following question arises: “What is the true treatment
ffect?” [2]. If there is heterogeneity, however—variation in true (or
nderlying) relative treatment effects for a particular pairwise
omparison—random-effects models must be used. A random-
ffects approach typically assumes that true relative effects across
tudies are considered exchangeable (i.e., the prior position of ex-
ecting underlying effects to be similar but not identical) and can
e described as a sample from a normal distribution whose mean
s the pooled relative effect and whose SD reflects the heterogene-
ty [2,30–33]. One could argue that with a random-effects model,
he question asked is “What is the average of the true treatment
ffects, and how much do these effects vary across trials?” [2].
ith a random-effects model for a network meta-analysis, the
ariance reflecting heterogeneity is often assumed to be constant
or all pairwise comparisons [9].
Although a random-effects model explicitly models heteroge-
eity, it does not explain heterogeneity. Extending network meta-
nalysis models with treatment-by-covariate interactions at-
empts to explain heterogeneity in relative treatment effects and
stimates relative treatment effects for different levels of the co-
ariate. As outlined previously, network meta-analysis will be bi-
sed if there are differences in covariates across those studies that
re indirectly compared and act as modifiers of the relative treat-
ent effect [15,21,27]. This implies that by taking into account
hese covariates with treatment-by-covariate interactions in a
eta-regression model (i.e., a model that includes study-level co-
ariates), the impact of bias due to similarity and/or consistency
iolations can be reduced [21]. (Covariates that vary across studies
ut are not effect modifiers do not need to be taken into consider-
tion in a meta-regression model.)
Unfortunately, the number of studies in a network is often lim-
ted, and in such cases, adjustment by incorporating study-level co-
ariates with meta-regression models may sometimes be question-
ble [15,34]. In addition, aggregate-level covariate adjustment might
roduce ecological bias, limiting the interpretation of estimated re-
ults for subgroups [34–36]. In contrast, patient-level networkmeta-
nalyses usually have sufficient power to estimate meta-regression
odels, thereby reducing inconsistency and providing the opportu-
ity to explore differences in effect among subgroups. However, ob-
aining patient-level data for all RCTs in the networkmay be consid-
red unrealistic. As an alternative, one could use patient-level data
hen available and aggregate-level data for studies in the networkor which such data are not available, thereby improving parameter
stimation over aggregate data–only models.
Because with a random-effects model the study-specific treat-
ent effects are explicitly modeled, a random-effects model “fits”
he data better than a fixed-effects model. Similarly, extending a
xed- or random-effectsmodel by incorporating treatment-by-cova-
iate interaction terms canalso improvemodel fit. For any givendata
et, however, the more parameters that need to be estimated, the
oreuncertain the estimates of theseparameterswill be.Hence, the
bjective is to use amodel that sufficiently fits the data (and reduces
onfounding bias) but that provides stable parameter estimates. The
hoice of a fixed- or random-effects meta-analysis model, with or
ithout covariate interactions, can be made by comparing different
ompeting models regarding their goodness-of-fit to the data. The
oodness-of-fit can be estimated by calculating the difference between
he deviance for the fitted model and the deviance for the saturated
odel (which fits the data perfectly). For example, the Akaike infor-
ation criterion, which uses the likelihood function, the Bayesian
nformation criterion, or deviance information criterion can all be
sed for model selection [37–39].
Network meta-analysis can be performed within a frequentist
r Bayesian framework. With a frequentist approach, the result of
he analysis is a point estimatewith a 95% confidence interval (CI).
he 95% CI, under repeated sampling, would contain the true pop-
lation parameter 95% of the time. It must be noted that CIs ob-
ained with a frequentist approach cannot be interpreted in terms
f probabilities; the 95% CI does not mean that there is 95% prob-
bility that “true” or population value is between the boundaries of
he interval [40].
Bayesian methods involve a formal combination of a prior
robability distribution, which reflects a prior belief of the possible
alues of themodel parameter of interest, with a likelihood distri-
ution of these parameters based on the observed data, to obtain a
orresponding posterior probability distribution [41]. The likeli-
ood informs us about the extent to which different values for the
arameter of interest are supported by the data [42]. The posterior
istribution, as obtained with the Bayesian approach, can be inter-
reted in terms of probabilities (e.g., “There is an x% probability that
reatment A results in a greater response than treatment B”). This is
ifferent from the interpretation of the findings within a conven-
ional frequentist approach. To not influence the observed results by
he prior distribution, an often-heard critique of the Bayesian ap-
roach, a noninformative prior distribution can be used for the treat-
ent effect parameter(s). With such a “flat” prior distribution, it is
ssumed that before seeing the data, any parameter value is
equally” likely. As a consequence, posterior results are not influ-
nced by the prior distribution but are driven by the data as in a
onventional frequentist meta-analysis.
A major advantage of the Bayesian approach is that the method
aturally leads to a decision framework that supports decisionmak-
ng [41–43]. For a networkmeta-analysis, a specific advantage is that
he posterior probability distribution allows calculating the probabil-
ty of which of the competing interventions is best and other proba-
ility statements [40]. This aspect of a Bayesian analysis is providing
nformation that is directly relevant to health-care decision makers
e.g., policymakers and health-care professionals/clinicians). As dis-
ussed later, however, there is a risk of overinterpreting this proba-
ility. Other advantages of a Bayesian meta-analysis include the
traightforwardway tomakepredictions and thepossibility to incor-
orate different sources of uncertainty [41,42].
Critically reviewing and interpreting a network
meta-analysis
To assist health-care decisionmakers in using the findings of net-
work meta-analyses, we describe in this section how to critically
review and interpret such studies. The importance of correctly
422 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8assessing results of network meta-analyses cannot be overstated
because these are intended to inform comparative effectiveness
choices and are likely to have coverage implications. Understand-
ing the validity of these studies is therefore critical. In the follow-
ing section, we briefly review issues related to internal and exter-
nal validity of network meta-analyses. We provide a list of items
that we recommend be reported for a network meta-analysis to
allow proper evaluation and interpretation of findings to inform
decision making.
Internal and external validity
Decision makers making use of results of network meta-analyses
will need to assess whether the differences between treatments
aremost likely true orwhether they can be explained by bias in the
analysis. The internal validity of the analyses is contingent on
three factors: 1) the appropriate identification of the studies that
make up the evidence network, 2) the quality of the individual
RCTs, and 3) the extent of confounding bias due to similarity and
consistency violations.
Appropriate search and selection methods of all relevant RCTs
must be conducted, although the delimitation of what constitutes
the evidence network is a matter of current research [44,45]. Nev-
ertheless, even with rigorous and extensive literature search
methods, the extent of publication bias must be assessed. It is
well-known that negative or small trials are less likely to be pub-
lished, so the evidence network may be limited accordingly [46].
Furthermore, in a network of RCTs, specific comparisons can
heavily outweigh less compared interventions, resulting in asym-
metrical networks [26]. The validity of a network meta-analysis
will also be contingent on the internal validity of the single RCTs
included in the evidence network. The inclusion of poor-quality
trials may be an issue. Randomization does not guarantee that an
RCT is unbiased [8,47,48]. There may be a lack of adequate alloca-
tion concealment; patients may be excluded after randomization,
which may result in an imbalance between groups; or a lack of
blinding of the outcome may overestimate the treatment effect
[49]. Thus, each RCT included in a network meta-analysis should
be critically evaluated for bias.
After addressing the threats to internal validity associatedwith
the development of the evidence network, the similarity between
the trials included in the network will also be a determinant of the
internal validity of the analyses. Studiesmay differ with respect to
the characteristics of the patients, the way in which the outcomes
were measured or defined, the protocol requirements including
the concomitant interventions allowed, the length of follow-up as
well as differential loss to follow-up, and the time frame during
which the studies were conducted [14].
As outlined earlier, a networkmeta-analysis is affected by con-
founding bias if there are differences across trials that are indi-
rectly compared regarding relative treatment effect modifiers.
This bias may be reduced by adjusting for these differences by
incorporating treatment-by-covariate interactions in the statisti-
cal models used. One can only judge, however, the similarity of
trials and potentially adjust for bias regarding study level covari-
ates that are measured. Hence, differences in baseline risks and
placebo responses across trials should be assessed because these
can reflect additional important differences in study or patient
characteristics across studies.
The external validity of the network meta-analysis will natu-
rally be limited by the external validity of the RCTs included in the
evidence network, and health-care decision makers will need to
review whether results can be extrapolated to the population of
interest. It is important to remember that registration trials for reg-
ulatory purposes are more likely to include selective homogeneous
populations, which compromises external validity [50,51]. From a
decision-making perspective, a certain degree of variation in the pa-
tient populations may be welcome for comparative and cost-effec-tiveness evaluations if it reflects real-world practice. Hence, some
heterogeneity across trials in the evidence network may arguably
increase external validity as long as the heterogeneity within direct
comparisons are greater than the variation of effectmodifiers across
studies that are indirectly compared to avoid similarity violations as
much as possible. Although we are not aware of any network meta-
analysis that evaluated this explicitly, a possible approach is by
means of an analysis of variance of thewithin versus between direct
comparisons relative treatment effects.
Reporting
In Table 1,we present a simplified checklist of items that should be
included in a report of a network meta-analysis to enable health-
care decision makers to interpret the findings on comparative
health outcomes. The checklist is not exhaustive but is intended
as a general guide. Some caution should be exercised when using
this list to judge the quality of published network meta-analyses
because this list focuses on reporting quality and does not capture
explicit items to judge or score the internal and external validity of
a network meta-analysis.
In the introductory section, a clear statement of the objectives
should clarify what the decision problem is, with a specific focus
on the patient population and the competing interventions of in-
terest. The treatments that will be compared in the networkmeta-
analysis may be limited to all drugs in a class, but can also include
competing drugs of different classes and, in some cases, other
medical interventions. Whatever the scope of interventions, a
clear rationale for the choice should be described.
In the methods section, the development of the evidence net-
work should be described and should follow systematic review
procedures that include an explicit search strategy in a variety of
databases and prespecified inclusion and exclusion criteria for the
study selection process. A protocol is recommended to describe
these elements as well as prespecify the outcomes to be analyzed
to avoid outcome selection bias [53]. Rigorous data extraction
methods should be used, and authors should indicate whether
double data extraction was performed, how disagreements were
resolved, and how missing data were handled. These methods
have been described in detail elsewhere (Centre for Reviews and
Dissemination Handbook) and should be reported following the
PRISMA statement [54,55].
The data analysis section should provide a comprehensive
overview of the statistical methods used, including the justifica-
tion of the choice of outcomes and endpoints, relative effect esti-
mates, the choice of fixed- or random-effects models, Authors
should also specify whether the models were extended with
study-level covariates to improve similarity and reduce inconsis-
tency. If the analyses were performed within a Bayesian frame-
work, the choice of prior distributions for the model parameters
should be defined. A description of different sensitivity analyses
pertaining to studies included in the networks and prior distribu-
tions (if applicable) should be reported.
It is not the mandate of the Task Force to be prescriptive in
recommending elements to be reported in the results section.
Nevertheless, we recommend that, at aminimum, the elements in
the following section be reported for users of a network meta-
analysis to be able to judge the internal validity of the analyses.
A list of the studies identified by the systematic review and
those included in the network meta-analysis should be provided.
In some instances, these will differ if there were insufficient data
reported in particular studies to include in the actual analysis. A
flow diagram that illustrates the way in which trials were selected
can be helpful. The reader is referred to the PRISMA statement for
specific recommendations on how to report the results of a sys-
tematic review [54]. A list of key patient and study characteristics
of each study should be provided in table format. This is essential
to judge whether there are differences across trials that might act
423V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8as effectmodifiers, thereby causing bias in the analysis. For exam-
ple, differences in patient age, length of time with a disease, or
Table 1 – Simplified checklist to assist decision makers in
Report section Checklist Item
Introduction Are the rationale for the study and the study o
stated clearly?
Methods Does the methods section include the followin
Description of eligibility criteria
Information sources
Search strategy
Study selection process
Data extraction (validity/quality assessment
individual studies)
Are the outcome measures described?
Is there a description of methods for analysis/
evidence? Do the methods described include
following?
Description of analyses methods/models
Handling of potential bias/inconsistency
Analysis framework
Are sensitivity analyses presented?
Results Do the results include a summary of the studi
in the network of evidence?
Individual study data?
Network of studies?
Does the study describe an assessment of mod
competing models being compared?
Are the results of the evidence synthesis (ITC/
presented clearly?
Sensitivity/scenario analyses
Discussion Does the discussion include the following?
Description/summary of main findings
Internal validity of analysis
External validity
Implications of results for target audiencehistory of treatmentmay constitute effectmodifiers. Also, the geo-graphic regions where the studies were performed may reflect
additional differences between patient populations not reflected
ating a reported network meta-analysis.
What to look for in the paper
ives A clear rationale for the review
A clear objective or research question that pertains to
the network meta-analysis
A systematic review of the literature in accordance
with Centre for Reviews and Dissemination (CRD)
guidelines and PRISMA [52,54,55]
Justification of outcome measures selected for analysis
esis of Description and justification of statistical model(s)
used: multiple meta-analysis of pairwise
comparisons vs. network meta-analysis models;
fixed- vs. random-effects models; models without or
with covariate (interactions)
Description of whether analyses were performed with
a frequentist or Bayesian approach
Description of how possible bias/inconsistency was
evaluated (either qualitative or quantitative, e.g.,
comparison of direct evidence with the indirect
evidence). If meta-regression models are used,
rationale for selection of covariates in models
Description of relative-effect estimates used for
presentation of findings (e.g., odds ratio, relative
risk, hazard ratio, difference in change from
baseline)
Description of whether relative-effect measures were
transformed into expected (absolute) outcomes (e.g.,
proportion of responders)
Rationale for and description of sensitivity analyses
Studies included
Prior distributions for model parameters in Bayesian
framework
luded Description of results of study identification and
selection process
Table/list of studies with information regarding study
design and patient characteristics (that might act as
effect modifiers); these are important to judge
potential similarity/consistency issues
Figure of network of studies
Table with raw data by study and treatment as used
for the analysis/model. (Optionally present relative
effects of available direct comparisons of each study)
? Are Justification of model results
Table/ figure with results for the pairwise comparisons
as obtained with analyses; Point estimates and
measure of uncertainty (95% CIs)
In Bayesian framework, probability to reflect decision
uncertainty (i.e., probability of which treatment is
best if multiple treatments are being compared and
probability that one treatment is better than the
comparator)
Description of (different) findings with
sensitivity/scenario analysis
Summary of findings
Internal validity (individual trials, publication bias,
differences across trials that might violate similarity
and consistency assumptions)
Discussion regarding generalizability of findings (given
patient population within and across trials in
network.)
Interpretation of results from a biological and clinical
perspectiveevalu
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424 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8evidence network with labels of the different RCTs can be helpful
and will improve transparency of the analyses.
Point estimates and the corresponding measures of uncer-
tainty should be reported for each (treatment arm) of the individ-
ual trials. Although the network meta-analysis uses the relative-
effectmeasures of the different trials, outcomes by treatment arm
for the individual studies provide important information. As illus-
trated in the example in Table 2 (based on Cipriani et al. [25]), this
acilitates the understanding of the network and provides a com-
arison of the common reference treatment (or placebo) outcomes
cross trials, which may help assess key differences among the
rials. Presenting relative treatment effects for each of the RCTs in
table or a figure such as a forest plot is also helpful and allows
omparisons between the pooled results of the network meta-
nalysis and the individual study results.
In the section of the report where the results of the network
eta-analysis are presented, competing models should be com-
ared in terms of their goodness-of-fit to the data, and residual
eviance calculationsmay be provided to justify the study’s choice
f the base case model. As a minimum, the estimates of relative
reatment effects (e.g., ORs, hazard ratios, differences in means)
long with 95% CI or credible intervals (depending on the frame-
ork of analysis) compared to a common reference treatment or
nchor should be reported (Table 3). In order to appreciate the
alue of a network meta-analysis, it is recommended that results
f all (relevant) pairwise comparisons (as a reflection of the func-
ional parameters) are presented as well (Table 4). Forest plots can
e very informative in presenting pairwise comparisons, as illus-
rated by Vissers et al. [24]. (Comment: Although the data of Cip-
iani et al. [25] were used to illustrate how source data and results
f a network meta-analysis can be presented, we like to point out
hat the use of these data does not imply endorsement of the
ndings by the ISPOR Task Force.)
It may sometimes be useful to decision makers to report esti-
ates of relative treatment effect on a different scale than that
sed for the model analysis. For example, it may be useful to the
eport results from a network meta-analysis conducted on an OR
s relative risks, absolute risk differences, and numbers needed to
reat. These estimates will depend on the estimated probability of
esponse for the reference treatment. Analyses using the (Bayes-
an) statistical software packageWinBUGS facilitate the derivation
f estimates of relative treatment effects on different scales [56].
If the analyses are performed within a Bayesian framework,
he uncertainty in the relative-effect estimates can be translated
nto probabilities of decision uncertainty. For example, the OR
long with the 95% credible intervals for each of the interventions
elative to a common anchor enables the calculation of the prob-
bility that each treatment is the most efficacious out of all treat-
ents compared. For example, in Table 3, there is a 39.2% proba-
ility that escitalopram shows the greatest acceptance (i.e., lowest
ropout rate) out of 12 antidepressants compared (before consid-
ring the available evidence, each treatment would have an a pri-
ri change of 100%/12  8.3%). Although this illustrates an impor-
ant advantage of the use of the Bayesian framework, caution
hould be applied when only the probability of a treatment being
est or ranked first is provided. This is because information of the
spread” of rankings for a treatment is also important. For exam-
le, a treatment for which there are few trial data and conse-
uently awide CImayhave a probability approaching 50%of being
he best treatment, butmay nevertheless have a probability of 50%
f being theworst treatment. It is therefore also useful to calculate
he expected ranking of efficacy for all treatments based on the
robabilities of all treatment rankings (i.e., probability of being the
est, probability of second best, and so on), as illustrated in Table
[25].
In addition to estimates of relative treatment effects, it maye useful to report estimates of the absolute probability of out-ome for binary outcomes. This will require an estimate of the
aseline probability for the anchor treatment. Thismay be derived
rom the trial data or other sources and may be subject to sensi-
ivity analyses. The method used to estimate the baseline proba-
ility should be clearly stated. In Table 3, we report the expected
ropout rate based on the results of the networkmeta-analysis by
ipriani et al. in combination with a fixed-effects estimate for the
ropout rate with fluoxetine as a reference.
Thediscussionsectionof a report shouldpresenta critical assess-
ent of the results with respect to internal and external validity.
uthors should provide a thoughtful discussion of the assumptions
f similarity and consistency and whether these can be assumed to
old for the analysis at hand. The discussion should also address
hether the networkmeta-analysis results are in line with expecta-
ions based on previousmeta-analyses and other (observational) ev-
dence available [57]. Furthermore, an explanation for observed dif-
erences between compared interventions from both biological and
linical perspectives is recommended. Apart from the appropriate-
essof the results, the relevanceof thefindings for real-worldclinical
nd reimbursement decision making should be addressed.
Interpretation of findings
After assessing the validity and results of a network meta-analy-
sis, decision makers will want to carefully consider whether the
findings can be applied to their decision problems. Is one treat-
ment better than another and do these results apply to the popu-
lation of interest to the decision maker?
Frequently, a small number of studies in a networkmeta-anal-
ysis limits the possibility to adjust for possible bias due to similar-
ity issues by means of statistical techniques. Rather than imme-
diately ignoring the results of the analysis by claiming that trials
are not comparable, the decision maker should make an attempt
to hypothesize the possible direction of bias in the indirect esti-
mates. An important question to ask is how different a nonbiased
indirect comparison would be and whether this would lead to a
different conclusion and decision.
An issue to consider is whether a treatment can be considered
more effective than another when only a limited number of out-
comes have been analyzed. Selection of outcomes analyzed must
be clearly justified at the outset of the analysis (for example, do
these reflect primary outcomes used in clinical trials?). Synthesiz-
ing the results ofmultiple networkmeta-analysesmust be consid-
ered. How dowe interpret situations in which drug A is better on a
number of clinical outcomes but not all of these outcomes? How is
the decision made in these cases? A possible approach is to weigh
the different end points based on the relative importance accord-
ing to the decision maker and calculate the probabilities of which
treatment is best, taking into account theseweights [58]. These are
not issues specific to a network meta-analysis. Indeed, the devel-
opment of measures such as the quality-adjusted life-year has
been fueled by the need to compare disparate health outcomes
using a common metric by means of decision models. Neverthe-
less, it is an issue to consider when interpreting a network meta-
analysis as well.
Furthermore identification of the “best” or most appropriate
treatment cannot be made on the basis of efficacy end points
alone. To inform health-care decision making for clinical treat-
ment guidelines and reimbursement policies, the efficacy findings
of a network meta-analysis must be interpreted in light of other
available (observational) evidence and other characteristics of the
competing interventions, such as safety and convenience.
The general development of evidence synthesis methods to
provide systematic exhaustive evidence on which to base deci-
sions has a natural place in comprehensive decision models that
include both costs and effects and are used to determine the cost-
effectiveness of interventions by such bodies as the NICE [5,59–
Table 2 – Example table how source data as used in a network meta-analysis can be presented - New-generation antidepressants for major depression, dropouts.
Study Fluoxetine Bupropion Citalopram Duloxetine Escitalopram Fluvoxamine Milnacipran Mirtazapine Paroxetine Reboxetine Sertraline Venlafaxine
r n r n r n r n r n r n r n r n r n r n r n r n
2906/421 45 119 50 123
29060/365 27 70 21 68
29060/785 43 207 41 199
Aberg-Wisted, 2000 26 177 33 176
Agren, 1999 8 133 18 137
Aguglia, 1993 31 56 17 52
AK130939 45 204 46 198
Akkaya, 2003 7 57 7 50
Alves, 1999 9 47 10 40
Amini, 2005 3 18 2 18
Annseaau, 1993 23 64 16 56
Annseau, 1994 18 93 23 97
Baldwin, 2005 15 166 14 159
Benkert, 1999 30 139 33 136
Bennie, 1995 23 144 24 142
· · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · · · ·
Detke, 2004 21 188 10 86
· · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · · · ·
· · · · · · · · · · · · · · · · · · · · · · · · ·
Zanardi, 1996 9 22 0 24
For complete dataset see Cipriani et al., 2009.
r, dropouts; n, number of patients. Reprinted from The Lancet, 373 (9665), Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H,
Tansella M, Barbui C, Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis, 746-58, 2009, with permission from Elsevier.
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426 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 861]. Network meta-analysis represents a valuable set of analytical
tools to inform clinical evidence in cost-effectiveness analysis.
Decision making in the absence of direct and
indirect treatment comparisons of RCTs
Pragmatic, randomized, naturalistic, head-to-head trials are argu-
ably the gold standard to obtain comparative effectiveness esti-
mates given their high internal and external validity [62]. These
trials, however, take a long time to complete and can never pro-
vide relative effectiveness information for all competing interven-
tions, especially when new treatments are developed continu-
ously. Hence, an ITC or network meta-analysis can be considered
a useful and realistic alternative. To minimize bias, a network
meta-analysis requires RCT evidence. Evidence from RCTs, how-
ever, may not be available in a significant proportion of situations
that decisionmakers face. For example, in oncology, Phase II trials
often have a single arm. A review of practice guidelines found that
few recommendations were based on high-quality evidence, and
many were based on expert opinion, individual case studies, and
standards of care [63]. There are often good reasons for the ab-
sence of RCTs. Time may be too short to conduct RCTs of rapidly
emerging technologies [64]. RCTs may be unethical if clinicians
believe that there is a causal association between the intervention
and the outcome, for example, between sleeping position and sud-
den infant death. Limited resources can also be a factor for the lack
of RCT evidence.
Whatever the reasons for the absence of RCTs and therefore
the absence of indirect treatment comparisons based on random-
ized evidence, health-care payers, health-care professionals, and
patients may need to make decisions. It is wrong to assume that
these stakeholders can postpone the decision and wait for the
“appropriate” evidence. In particular, decisions have to be made
based on the available set of possible choices. In reality, not cov-
ering or prescribing an intervention is a tacit decision to stay with
the status quo. This decision has societal implications. It may or
Table 3 – Sample table showing how results of a network m
Odds ratio for
acceptability*
95% Credible
interval
Estimated
dropout, %†
Fluoxetine 1.0 Reference 27.0
Bupropion 1.12 (0.92–1.36) 24.8
Citalopram 1.11 (0.91–1.37) 25.0
Duloxetine 0.84 (0.64–1.10) 30.6
Escitalopram 1.19 (0.99–1.44) 23.7
Fluvoxamine 0.82 (0.62–1.07) 31.1
Milnacipran 0.97 (0.69–1.32) 27.6
Mirtazapine 0.97 (0.77–1.21) 27.6
Paroxetine 0.91 (0.79–1.05) 28.9
Reboxetine 0.70 (0.53–0.92) 34.6
Sertraline 1.14 (0.96–1.36) 24.5
Venlafaxine 0.94 (0.81–1.09) 28.2
Relative treatment effect of each treatment relative to reference com
outcome (with 95% credible intervals), and probability best as a mea
depression, acceptability (dropouts).
Based on Cipriani et al. [25].
Reprinted from The Lancet, 373 (9665), Cipriani A, Furukawa TA, Sala
IM, McGuire H, Tansella M, Barbui C, Comparative efficacy and acc
meta-analysis, 746-58, 2009, with permission from Elsevier.
* Odds ratio 1 favors fluoxetine; odds ratio reflects odds of accepta
† Reference dropout was based on fixed-effects meta-analysis of fluo
‡ Reported by Cipriani et al. [25].may not maximize health benefits for the population (if made by ethe decision maker) or health benefits for the patient (if made by
the health-care provider and patient) [65].
A critical question for decision makers, then, is whether to
se observational comparative studies if RCTs or indirect com-
arisons of RCTs are not available. To answer this question, it is
mportant to remember that in a network meta-analysis of
CTs, the value of randomization does not hold across trials. If
tudy or patient characteristics differ among trials for interven-
ions indirectly compared and are modifiers of relative treat-
ent effects, the analysis will be biased. Hence, an ITC or net-
ork meta-analysis of RCTs is a form of observational evidence,
ut arguably less prone to confounding bias than is a cohort study
or any other observational design). A cohort study is biased if
ifferences in unmeasured covariates affect both the intervention
nd the outcome, whereas an ITC or network meta-analysis of
CTs is biased only if differences in unmeasured covariates
mong trials are modifiers of relative treatment effects, which is
rguably much more unlikely. Thus, asking whether comparative
bservational studies should be used in the absence of an ITC or
etwork meta-analysis of RCTs is synonymous with asking what
evel of observational evidence can be considered to have suffi-
ient internal validity to inform decision making; or, more specif-
cally, withwhat level of observational evidence are decisionmak-
rs comfortable? Is theminimumacceptable level of observational
vidence an ITC or network meta-analysis of RCTs or is a cohort
tudy sufficient?
To answer such questions, decision makers must recognize
hat the lower the internal validity, the greater the risk of biased
esults and therefore the greater the risk of making an inferior
ecision. If the new treatment is chosen over the standard treat-
ent because of biased estimates of comparative effectiveness,
nd the true outcomes favor the standard treatment, then health
enefits are foregone.
The debate over the proper use of RCT evidence, indirect com-
arison of RCTs, and “traditional” observational studies is likely to
ontinue. Observational studies can be considered complemen-
ary evidence to RCTs [66]. Fortunately, the needs for comparative
-analysis can be presented.
95%
edible
terval
Probability of being
among the four
best treatments, %‡
Probability of being
the best out of all
compared, %
Rank
3.4 0.0 5
%–28.6%) 19.3 16.9 3
%–29.0%) 18.7 15.3 4
%–36.5%) 0.7 0.3 10
%–27.2%) 27.6 39.2 1
%–37.1%) 0.4 0.2 11
%–34.5%) 7.1 6.4 6
%–32.3%) 4.4 1.9 7
%–31.9%) 0.2 0.0 9
%–41.0%) 0.1 0.0 12
%–27.8%) 21.3 19.8 2
%–31.3%) 0.9 0.1 8
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427V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 4 1 7 – 4 2 8thesis and its understanding. At this stage, we conclude that, in
the absence of (head-to-head) RCTs, decision makers can use ob-
servational evidence as long as they are aware of the potential
risks in using evidence of lower quality and are comfortable taking
these risks. If decision makers prefer to wait for head-to-head
RCTs or, the next best thing, an ITC of RCTs, theymust realize that
they are choosing the “old” treatment over the “new” treatment,
with potential societal implications.
In essence, for every appraisal of a new intervention, a decision
makermustmake the trade-off between, on the one hand, the risk
of making the wrong decision and therefore losing health benefits
by relying on lower quality evidence and, on the other hand, post-
poning the decision and therefore possibly also forgoing health
benefits. This trade-off is influenced by considerations including
the burden of disease and the number of currently available treat-
ments. Whatever the outcome of the debate, the quality of deci-
sion making will be increased by being transparent and explicit
about which type of evidence is being used and evaluating its lim-
itations and consequences.
Conclusion
This report, the first part of the report from the Task Force, out-
lines the key concepts of ITC and MTC and provides guidance for
reviewing and interpreting these studies to inform decision mak-
ing. Network meta-analysis can be considered an extension of
traditional meta-analysis by including multiple different pairwise
comparisons across a range of different interventions to allow
multiple treatment comparisons in the absence of head-to-head
evidence. Furthermore, the methodology can combine direct and
indirect treatment comparisons, thereby synthesizing a greater
share of the available evidence than a traditional meta-analysis.
Although the evidence networks underlying network meta-anal-
ysis typically include RCTs, randomization does not hold across
trials and there is a risk of confounding bias, compromising inter-
nal validity. Accordingly, a network meta-analysis must be con-
sidered observational evidence, but is arguably less prone to con-
founding bias than an observational comparative (prospective)
cohort study. Although the methodological issues regarding indi-
rect comparisons and network meta-analysis are recognized, ap-
plication of this method is expected to continue and grow, simply
because failing to view accumulation of information as an evolv-
ing process would undermine the role played by scientific evi-
dence in shaping health-care decisionmaking. For that reason, the
goal of the Task Force is to help educate policymakers and health-
care professionals about these studies and identify areas for future
research.
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